RxDoctor Payments Data

Martha Magnuson, MD

Rheumatology · Jackson, MSNPI 1073000394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.2% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 39.8% of the total. That places this record below the midpoint for rheumatology clinicians in MS, where the typical reported total is $8,210.

$2,878in general payments, 2019–2025

Across 145 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Aurinia Pharma U.S., Inc.$451
  • Johnson & Johnson$304
  • Amgen$276
  • Novartis$206
  • AstraZeneca$125
  • plus $370 from 9 others

What the payments were for

  • Food & beverage$2,74095%
  • Education$1385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,878 in reported general payments places this provider in the 40th percentile of 44 rheumatology providers in Mississippi.

See all rheumatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$46,622
Medicare patients
231
Services billed
519

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept17$113,121
RinvoqUpadacitinib18$111,392
BenlystaBelimumab13$61,941
TymlosAbaloparatide18$51,953
ProliaDenosumab11$18,713
Hydroxychloroquine Sulfate165$5,368
MethotrexateMethotrexate Sodium145$2,363
Duloxetine Hcl29$1,478
Prednisone221$1,012
Colchicine13$984
Mycophenolate Mofetil11$644
Azathioprine22$610
Pregabalin18$520
Allopurinol51$324
Folic Acid31$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$1,146$111,39218 claims
GSKBenlysta$36$61,94113 claims
AmgenProlia$276$18,71311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 44 rheumatology providers in Mississippi.

Other rheumatology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →